Janux Therapeutics Inc
NASDAQ:JANX
Balance Sheet
Balance Sheet Decomposition
Janux Therapeutics Inc
Janux Therapeutics Inc
Balance Sheet
Janux Therapeutics Inc
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
1
|
8
|
36
|
51
|
19
|
0
|
|
| Cash |
1
|
8
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
36
|
51
|
19
|
0
|
|
| Short-Term Investments |
0
|
0
|
339
|
276
|
325
|
0
|
|
| Total Receivables |
0
|
8
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
8
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
2
|
5
|
5
|
8
|
|
| Total Current Assets |
1
|
16
|
377
|
332
|
349
|
1 034
|
|
| PP&E Net |
0
|
0
|
2
|
29
|
28
|
24
|
|
| PP&E Gross |
0
|
0
|
2
|
29
|
28
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
3
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
2
|
3
|
3
|
|
| Total Assets |
1
N/A
|
16
+2 214%
|
380
+2 244%
|
364
-4%
|
380
+4%
|
1 062
+179%
|
|
| Liabilities | |||||||
| Accounts Payable |
0
|
0
|
3
|
2
|
2
|
4
|
|
| Accrued Liabilities |
0
|
1
|
4
|
9
|
9
|
13
|
|
| Short-Term Debt |
4
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
2
|
6
|
6
|
2
|
0
|
|
| Total Current Liabilities |
5
|
3
|
13
|
17
|
13
|
17
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
6
|
1
|
27
|
23
|
21
|
|
| Total Liabilities |
5
N/A
|
9
+100%
|
14
+47%
|
43
+221%
|
36
-17%
|
39
+8%
|
|
| Equity | |||||||
| Common Stock |
4
|
22
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
8
|
15
|
47
|
111
|
169
|
238
|
|
| Additional Paid In Capital |
0
|
0
|
414
|
433
|
512
|
1 258
|
|
| Other Equity |
0
|
0
|
0
|
2
|
1
|
2
|
|
| Total Equity |
4
N/A
|
7
N/A
|
366
+5 133%
|
321
-12%
|
344
+7%
|
1 023
+197%
|
|
| Total Liabilities & Equity |
1
N/A
|
16
+2 214%
|
380
+2 244%
|
364
-4%
|
380
+4%
|
1 062
+179%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
40
|
40
|
42
|
42
|
46
|
59
|
|